
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
Days have lengthened and, as the summer sun beckons, the American Academy of Pediatrics offers advice for parents and pediatricians. Much of it is familiar, but some is new. Among the less familiar:






